Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 9/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262303 | 0.86 | GAA (0.48) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL10385396 | 0.86 | ALDH1A1 (0.58) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL1243574 | 0.83 | MEN1 (0.50) | GAAALOX15MEN1KMT2ACASP3 | |
| SCHEMBL1242660 | 0.83 | MAPK1 (0.58) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL262175 | 0.81 | GAA (0.48) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL4493859 | 0.80 | GAA (0.52) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL10385859 | 0.79 | KDM4E (0.50) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL1243899 | 0.78 | MEN1 (0.50) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL1243945 | 0.74 | MEN1 (0.49) | GAAALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL1243987 | 0.73 | MEN1 (0.46) | GAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879878-B2 | such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-7488739-B2 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20060148806-A1 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1650192-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | GAA 1758/4885ALOX15 1885/4885ALDH1A1 2093/4885 |
| US-20060148806-A1 | Quinolone derivative or salt thereof | THPO, ABL1, GMPS | GAA 1758/4885ALOX15 1885/4885ALDH1A1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.